{"id":452210,"date":"2021-03-08T02:33:09","date_gmt":"2021-03-08T07:33:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452210"},"modified":"2021-03-08T02:33:09","modified_gmt":"2021-03-08T07:33:09","slug":"avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/","title":{"rendered":"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants <\/b><\/p>\n<p class=\"bwalignc\"><i>Avacta\u2019s AffiDX SARS-CoV-2 lateral flow test detects both B117 \u2018Kent\u2019 and D614G variants of the virus<\/i><\/p>\n<p>CAMBRIDGE, England &amp; WETHERBY, England&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAvacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer<sup>\u00ae<\/sup> and pre|CISION<sup>\u2122<\/sup> platforms, announces that the AffiDX<sup>\u00ae <\/sup>SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or \u2018Kent\u2019, variant, and the D614G variant, as well as the original strain.\n<\/p>\n<p>\nThe SARS-CoV-2 virus, like most viruses, mutates over time into slightly different variants. Some of these variants are more infectious, and therefore more rapidly transmissible, and have the potential to become dominant strains.\n<\/p>\n<p>\nEarly on in the pandemic a variant referred to as D614G appeared, which rapidly became the dominant strain globally<sup>1<\/sup>. The B117 variant, which was first observed in Kent, is prevalent in the UK, has been found in more than 50 countries and, according to Professor Sharon Peacock (Professor of Public Health and Microbiology at Cambridge University) is likely to become the next dominant strain globally<sup>2<\/sup>.\n<\/p>\n<p>\nAvacta has carried out analytical tests with the spike proteins isolated from both the B117 and D614G variants, and has confirmed that its AffiDX<sup>\u00ae<\/sup> SARS-CoV-2 rapid antigen lateral flow test detects both of these variants as well as the original strain.\n<\/p>\n<p><b>Dr Alastair Smith, Chief Executive of Avacta Group commented:<\/b><\/p>\n<p>\n\u201cWe are pleased to confirm that Avacta\u2019s rapid antigen test detects the B117 strain, an important variant of the SARS-CoV-2 virus and one which is especially prevalent in the UK. We have also shown that our test detects the D614G variant, the current dominant global strain.\n<\/p>\n<p>\nWe will continue to monitor the performance of the Affimer reagents with future dominant variants as they become available to us. Since the Affimer reagents we use in Avacta\u2019s range of SARS-CoV-2 tests do not bind in the region of the spike protein where the dominant mutations appear, we do not anticipate that the performance of the tests will be affected.\n<\/p>\n<p>\nNow that we have developed a robust lateral flow test architecture, we can easily insert Affimer reagents that can be very rapidly developed for new variants if necessary, and indeed in response to any other future pandemic virus.\n<\/p>\n<p>\nOur next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved.\u201d\n<\/p>\n<p><i>This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596\/2014 (MAR).<\/i><\/p>\n<p><i>Disclaimer: AffiDX<\/i><sup>\u00ae<\/sup><i> SARS-CoV-2 Lateral Flow Rapid Antigen Test not currently for sale in the United States.<\/i><\/p>\n<p><b>Further information<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>1 <\/sup><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-020-2895-3&amp;esheet=52391967&amp;newsitemid=20210307005079&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-020-2895-3&amp;index=1&amp;md5=08ec1eeb4e079a573bfbb0693338e289\">https:\/\/www.nature.com\/articles\/s41586-020-2895-3<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>2 <\/sup><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.itv.com%2Fnews%2F2021-02-11%2Fcovid-kent-variant-will-become-dominant-strain-globally-scientist-says&amp;esheet=52391967&amp;newsitemid=20210307005079&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.itv.com%2Fnews%2F2021-02-11%2Fcovid-kent-variant-will-become-dominant-strain-globally-scientist-says&amp;index=2&amp;md5=882dd63bbc0a4d4608933c039f9a1fc7\">https:\/\/www.itv.com\/news\/2021-02-11\/covid-kent-variant-will-become-dominant-strain-globally-scientist-says<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210307005079\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210307005079\/en\/<\/a><\/span><\/p>\n<p><b>Zyme Communications <\/b>(Trade and Regional Media)<br \/>\n<br \/>Katie Odgaard<br \/>\n<br \/>Tel: +44 (0) 7787 502 947<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:katie.odgaard@zymecommunications.com\">katie.odgaard@zymecommunications.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases Clinical Trials Biotechnology General Health Pharmaceutical Health Science Oncology Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210307005079\/en\/863621\/3\/Avacta_logo_viewimage.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants Avacta\u2019s AffiDX SARS-CoV-2 lateral flow test detects both B117 \u2018Kent\u2019 and D614G variants of the virus CAMBRIDGE, England &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211; Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer\u00ae and pre|CISION\u2122 platforms, announces that the AffiDX\u00ae SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or \u2018Kent\u2019, variant, and the D614G variant, as well as the original strain. The SARS-CoV-2 virus, like most viruses, mutates over time into slightly different variants. Some of these variants are more infectious, and therefore more rapidly transmissible, and have the potential to become &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452210","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants Avacta\u2019s AffiDX SARS-CoV-2 lateral flow test detects both B117 \u2018Kent\u2019 and D614G variants of the virus CAMBRIDGE, England &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211; Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer\u00ae and pre|CISION\u2122 platforms, announces that the AffiDX\u00ae SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or \u2018Kent\u2019, variant, and the D614G variant, as well as the original strain. The SARS-CoV-2 virus, like most viruses, mutates over time into slightly different variants. Some of these variants are more infectious, and therefore more rapidly transmissible, and have the potential to become &hellip; Continue reading &quot;Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-08T07:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants\",\"datePublished\":\"2021-03-08T07:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/\"},\"wordCount\":552,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/\",\"name\":\"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-08T07:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/","og_locale":"en_US","og_type":"article","og_title":"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants - Market Newsdesk","og_description":"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants Avacta\u2019s AffiDX SARS-CoV-2 lateral flow test detects both B117 \u2018Kent\u2019 and D614G variants of the virus CAMBRIDGE, England &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211; Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer\u00ae and pre|CISION\u2122 platforms, announces that the AffiDX\u00ae SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or \u2018Kent\u2019, variant, and the D614G variant, as well as the original strain. The SARS-CoV-2 virus, like most viruses, mutates over time into slightly different variants. Some of these variants are more infectious, and therefore more rapidly transmissible, and have the potential to become &hellip; Continue reading \"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-08T07:33:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants","datePublished":"2021-03-08T07:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/"},"wordCount":552,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/","name":"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-08T07:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210307005079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avactas-rapid-antigen-test-is-confirmed-to-detect-sars-cov-2-new-variants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avacta\u2019s Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452210"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452210\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}